Business
Cerus Corporation and the Swiss Red Cross Celebrate 10 Years of Routine Use of INTERCEPT Blood System for Platelets
The Swiss Red Cross is a global pioneer in the nationwide adoption of Cerus’ pathogen inactivation technology CONCORD, Calif.--(BUSINESS WIRE)-- Cerus
About this update from Cerus Corporation
[{"type":"text","content":"\nThe Swiss Red Cross is a global pioneer in the nationwide adoption of Cerus’ pathogen inactivation technology\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS), a company solely dedicated to safeguarding the global blood supply, and the Transfusion Service of the Swiss Red Cross (Blutspende SRK Schweiz) announced today the tenth anniversary of the use of the INTERCEPT Blood System for its entire platelet supply in Switzerland.\n\n“We are honored to mark the tenth anniversary of the routine use of INTERCEPT platelets with our long-time partners at the Swiss Red Cross,” stated William ‘Obi’ Greenman, president and chief executive officer of Cerus Corporation. “The transfusion medicine community in Switzerland has long been vigilant with regard to blood safety and was among the earliest adopters of our technology at scale. The Swiss Red Cross recognized early on the value in implementing a proactive, ‘always on’ approach to increasing the safety of the country’s platelet supply. In this era of pandemic preparedness, we look forward to supporting their pioneering vision around blood safety and availability.”\n\nSince the Swiss Red Cross implemented the INTERCEPT Blood System for platelets, Cerus has provided INTERCEPT platelet kits for approximately 400,000 transfusable platelet units in Switzerland with no reports of transfusion-transmitted infections, transfusion-associated sepsis cases, fatalities or other long-term adverse side effects observed. Additionally, hemovigilance data for Switzerland’s routine use of INTERCEPT platelets have shown no increase in the use of platelets to treat patients.\n\n“Cerus and the INTERCEPT platform have been essential contributors to our success in providing for the safety and availability of the platelet supply in Switzerland over the last decade. The INTERCEPT System’s ability to inactivate bacteria has given us peace of mind in the ability to transfuse patients without the threat of contamination,” stated Bernhard Wegmüller, chairman and chief executive officer of the Swiss Red Cross Transfusion Service. “With emerging pathogens now fully recognized as a continued reality in medicine, we are further assured by the additional layer of safety that this technology provides for our patients receiving platelet transfusions,” Mr. Wegmüller continued.\n\n“As the FDA complianc...